Prions and their partners in crime
The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
Prions, the infectious agents of transmissible spongiform encephalopathies (TSEs), have defied full characterization for decades. The dogma has been that prions lack nucleic acids and are composed of a pathological, self-inducing form of the host's prion protein (PrP). Recent progress in propagating TSE infectivity in cell-free systems has effectively ruled out the involvement of foreign nucleic acids. However, host-derived nucleic acids or other non-PrP molecules seem to be crucial. Interactions between TSE-associated PrP and its normal counterpart are also pathologically important, so the physiological functions of normal PrP and how they might be corrupted by TSE infections have been the subject of recent research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PrPSc levels are in many cases poorly correlated with prion disease progression, suggesting that it is necessary but not sufficient; ‘something else’ is required”
Citations
Cites
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Self-citationThe cellular prion protein binds copper in vivo
Brown, D. R., Qin, K., Herms, J. W., Madlung, A., Manson, J., Strome, R., Fraser, P. E., Kruck, T., von Bohlen, A., Schulz-Schaeffer, W., et al. (1997) · Nature · doi:10.1038/37783 · Cited by 1,273
Legname, G., Baskakov, I. V., Nguyen, H.-O. B., Riesner, D., Cohen, F. E., DeArmond, S. J., & Prusiner, S. B. (2004) · Science · doi:10.1126/science.1100195 · Cited by 1,021 · cited 1×
“One team showed that synthetic truncated PrP fibril preparations can induce TSE disease when inoculated into transgenic mice that vastly overexpress the same truncated PrP construc”
BackgroundCells release prions in association with exosomes
Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., & Raposo, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308413101 · Cited by 997
S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration
Uehara, T., Nakamura, T., Yao, D., Shi, Z.-Q., Gu, Z., Ma, Y., Masliah, E., Nomura, Y., & Lipton, S. A. (2006) · Nature · doi:10.1038/nature04782 · Cited by 906
The most infectious prion protein particles
Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., & Caughey, B. (2005) · Nature · doi:10.1038/nature03989 · Cited by 899 · cited 2×
“To better characterize the minimal infectious unit and the most infectious particles per unit protein, Silveira et al.(17) developed new methods for gently disaggregating scrapie prion aggregates in detergent and separating them by size using flow field-flow fractionation.”
MethodSelf-citationNormal host prion protein necessary for scrapie-induced neurotoxicity
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., & Aguzzi, A. (1996) · Nature · doi:10.1038/379339a0 · Cited by 810 · cited 1×
“This is consistent with earlier studies that described reduced PrPres-induced neuropathology in brain tissue that lacks PrP C (ref”
ResultPrion protein is necessary for normal synaptic function
Collinge, J., Whittington, M. A., Sidle, K. C. L., Smith, C. J., Palmer, M. S., Clarke, A. R., & Jefferys, J. G. R. (1994) · Nature · doi:10.1038/370295a0 · Cited by 799
In Vitro Generation of Infectious Scrapie Prions
Castilla, J., Saá, P., Hetz, C., & Soto, C. (2005) · Cell · doi:10.1016/j.cell.2005.02.011 · Cited by 790 · cited 1×
“have demonstrated the cell-free propagation of PrPres and accompanying robust TSE infectivity, but many molecules besides PrP were also presen”
BackgroundDepleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis
Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P.-C., Brandner, S., & Collinge, J. (2003) · Science · doi:10.1126/science.1090187 · Cited by 770
Research works printed but not linked: 1
- Ben-Zaken, O. et al. Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem. 278, 40041–40049 (2003). · DOI · Paper page
Cited by
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
Generating a Prion with Bacterially Expressed Recombinant Prion Protein
Wang, F., Wang, X., Yuan, C.-G., & Ma, J. (2010) · Science · doi:10.1126/science.1183748 · Cited by 661
Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 618
Physiology of the prion protein
Linden, R., Martins, V. R., Prado, M. A. M., Cammarota, M., Izquierdo, I., & Brentani, R. R. (2008) · Physiological Reviews · doi:10.1152/physrev.00007.2007 · Cited by 617
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
“Even if infectivity is entirely deciphered in the conformation of PrPSc, it seems plausible that auxiliary components can significantly modulate various aspects in the pathogenesis of prion dis- eases (for a review, see Caughey and Baron, 2006).”
BackgroundKell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“Prion diseases: including transmissible spongiform encephalopathies and Creutzfeldt–Jakob disease A particularly striking set of diseases, where the down- stream events manifest as extreme cellular destruction leading to large areas of (brain) tissue disappearing com- pletely, are represented by the prion diseases, in…”
BackgroundInfluentialAtarashi, R., Moore, R. A., Sim, V. L., Hughson, A. G., Dorward, D. W., Onwubiko, H. A., Priola, S. A., & Caughey, B. (2007) · Nature Methods · doi:10.1038/nmeth1066 · Cited by 350
“15 20 25 (1) (2) (3) (1) (2) (3) (1) (2) (3) (1) (2) (3) 2 ag 10 ag 20 ag 50 ag ScBH”
Self-citationImplications of peptide assemblies in amyloid diseases
Ke, P. C., Sani, M.-A., Ding, F., Kakinen, A., Javed, I., Separovic, F., Davis, T. P., & Mezzenga, R. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00372b · Cited by 338
Molecular architecture of human prion protein amyloid: A parallel, in-register β-structure
Cobb, N. J., Sönnichsen, F. D., Mchaourab, H., & Surewicz, W. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706522104 · Cited by 326
Getting a Grip on Prions: Oligomers, Amyloids, and Pathological Membrane Interactions
Caughey, B., Baron, G. S., Chesebro, B., & Jeffrey, M. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082907.145410 · Cited by 323
“Another potential spreading mechanism is the transfer of membrane-associated PrPres between cells via recently described entities called tunneling nanotubes (89, 103, 104).”
BackgroundSelf-citationCell-to-cell transmission of non-prion protein aggregates
Lee, S.-J., Desplats, P., Sigurdson, C., Tsigelny, I., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.145 · Cited by 309
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration
Walsh, D. M., & Selkoe, D. J. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.13 · Cited by 294
Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome
Kristiansen, M., Deriziotis, P., Dimcheff, D. E., Jackson, G. S., Ovaa, H., Naumann, H., Clarke, A. R., van Leeuwen, F. W. B., Menéndez-Benito, V., Dantuma, N. P., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.001 · Cited by 263
“Studies support localization at the plasma membrane and in the endolysosomal compartment (Caughey and Baron, 2006).”
BackgroundResenberger, U. K., Harmeier, A., Woerner, A. C., Goodman, J. L., Müller, V., Krishnan, R., Vabulas, R. M., Kretzschmar, H. A., Lindquist, S., Hartl, F. U., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.86 · Cited by 248
“While different PrPC-dependent path- ways and -interacting proteins have been described (reviewed in Caughey and Baron, 2006), experimental evidence for a direct role of these components in PrPSc- or Ab-induced toxicity is missing.”
BackgroundDeleault, N. R., Piro, J. R., Walsh, D. J., Wang, F., Ma, J., Geoghegan, J. C., & Supattapone, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204498109 · Cited by 245
“Cell culture and biochemical studies have implicated several classes of macromolecules such as GAGs, nucleic acids, proteins, and lipids as potential cofactors for prion formation (3).”
BackgroundDesign and construction of diverse mammalian prion strains
Colby, D. W., Giles, K., Legname, G., Wille, H., Baskakov, I. V., DeArmond, S. J., & Prusiner, S. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910350106 · Cited by 230
Prion Diseases and Their Biochemical Mechanisms
Cobb, N. J., & Surewicz, W. K. (2009) · Biochemistry · doi:10.1021/bi900108v · Cited by 209
“Polyanionic glycans such as heparin sulfate are another important player; they have been identified as a cell-surface receptor involved in prion uptake, as well as modulators of prion protein conversion and PrPSc propagation (20).”
Prion-like aggregation of mutant p53 in cancer
Silva, J. L., Gallo, C. V. D. M., Costa, D. C. F., & Rangel, L. P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.001 · Cited by 201
Ramanan, V. K., & Saykin, A. J. (2013) · Europe PMC (PubMed Central) · Cited by 259
Helmus, J. J., Surewicz, K., Nadaud, P. S., Surewicz, W. K., & Jaroniec, C. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711716105 · Cited by 184
The Prion Protein Knockout Mouse: A Phenotype Under Challenge
Steele, A. D., Lindquist, S., & Aguzzi, A. (2007) · Prion · doi:10.4161/pri.1.2.4346 · Cited by 157
“Finally, (5) the OR region stabilizes the interaction between PrP and PrPR, but does not contribute directly to signaling.”
BackgroundGroveman, B. R., Dolan, M. A., Taubner, L. M., Kraus, A., Wickner, R. B., & Caughey, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.578344 · Cited by 161
“PrP is a glycophosphatidylinositol (GPI)anchored glycoprotein, the physiological and pathophysiological functions of which remain unclear (4, 5).”
BackgroundSelf-citationGroEL stimulates protein folding through forced unfolding
Lin, Z., Madan, D., & Rye, H. S. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1394 · Cited by 147
Prion Diseases: From Protein to Cell Pathology
Kovács, G. G., & Budka, H. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070442 · Cited by 174
“Subcellular subcompartments may, at least in part, be the site of PrP - PrP transformation as well as of PrP generation.(3,36,74,75) Pathogenic PrP oligomers may be released from the host cells to the extracellular space by direct recycling and/or via exosome secretion.”
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules
Linden, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00077 · Cited by 143
“Research on PrPC-binding partners was originally directed at the identification of a so-called ‘‘protein X’’, participant in the conversion of PrPC into the scrapie form (Yehiely et al., 1997), or otherwise involved in the formation and propagation of prions (Caughey and Baron, 2006).”
BackgroundMouse neuroblastoma cells release prion infectivity associated with exosomal vesicles
Alais, S., Simoes, S., Baas, D., Lehmann, S., Raposo, G., Darlix, J. L., & Leblanc, P. (2008) · Biology of the Cell · doi:10.1042/bc20080025 · Cited by 140
“However, none of the reports provided conclusive evidence that the infectious agent was composed entirely of the malformed prion protein PrPSc (Caughey and Baron, 2006).”
BackgroundRapid cell-surface prion protein conversion revealed using a novel cell system
Goold, R., Rabbanian, S., Sutton, L., André, R., Arora, P., Moonga, J., Clarke, A. R., Schiavo, G., Jat, P., Collinge, J., et al. (2011) · Nature Communications · doi:10.1038/ncomms1282 · Cited by 169
Smith, P. E. S., Brender, J. R., & Ramamoorthy, A. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809002a · Cited by 140
Evolutionary Descent of Prion Genes from the ZIP Family of Metal Ion Transporters
Schmitt-Ulms, G., Ehsani, S., Watts, J. C., Westaway, D., & Wille, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007208 · Cited by 135
Advanced tests for early and accurate diagnosis of Creutzfeldt–Jakob disease
Zanusso, G., Monaco, S., Pocchiari, M., & Caughey, B. W. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.65 · Cited by 142
Self-citationEvidence for the Benefits of Melatonin in Cardiovascular Disease
Tobeiha, M., Jafari, A., Fadaei, S., Mirazimi, S. M. A., Dashti, F., Amiri, A., Khan, H. Z., Asemi, Z., Reiter, R. J., Hamblin, M. R., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.888319 · Cited by 139
“The normal protein PrPC (cellular prion protein) is an ubiquitous glycoprotein anchored to the cell membrane via glycosylphosphatidylinositol, which is conserved across species (184).”
BackgroundDeriziotis, P., André, R., Smith, D. M., Goold, R., Kinghorn, K. J., Kristiansen, M., Nathan, J. A., Rosenzweig, R., Krutauz, D., Glickman, M. H., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.224 · Cited by 137
“Indeed, many pathways have been proposed to explain precise mechanisms of neuronal cell death in prion disease (Caughey and Baron, 2006; Collinge and Clarke, 2007; Tatzelt and Schatzl, 2007).”
BackgroundSilva, J. L., Vieira, T. C. R. G., Gomes, M. P. B., Bom, A. P. A., Lima, L. M. T. R., Freitas, M. S., Ishimaru, D., Cordeiro, Y., & Foguel, D. (2010) · Accounts of Chemical Research · doi:10.1021/ar900179t · Cited by 118
Molecular Pathology of Human Prion Diseases
Kovács, G. G., & Budka, H. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10030976 · Cited by 133
“The endosomal-lysosomal system is involved in the processing of both PrP and PrP, and it may even be the site of PrP–PrP transformation [2,25,118,119].”
BackgroundPrion protein: From physiology to cancer biology
Mehrpour, M., & Codogno, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.009 · Cited by 116
“Recently several excellent reviews have summarized the basic processes: the pathogenic pathways that lead to tissue pathology in different forms of prion disease and phenotype variability (see [10–12,4] for review).”
BackgroundEmerging physiological and pathological implications of tunneling nanotubes formation between cells
Sisakhtnezhad, S., & Khosravi, L. (2015) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2015.06.010 · Cited by 126
Calderón‐Garcidueñas, L., Ávila-Ramírez, J., Calderón‐Garcidueñas, A. L., González-Heredia, T., Acuña-Ayala, H., Chao, C., Thompson, C., Ramos, R. R., Cortés-González, V., Martínez-Martínez, L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160472 · Cited by 120
Selective Incorporation of Polyanionic Molecules into Hamster Prions
Geoghegan, J. C., Valdes, P. A., Orem, N. R., Deleault, N. R., Williamson, R. A., Harris, B. T., & Supattapone, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704447200 · Cited by 112
Evidence That Bank Vole PrP Is a Universal Acceptor for Prions
Watts, J. C., Giles, K., Patel, S. S., Oehler, A., DeArmond, S. J., & Prusiner, S. B. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003990 · Cited by 136
“Two explanations seem plausible for the promiscuity of bank voles for replicating prions originating in diverse species: first, the presence of an especially permissive prion replication cofactor [17,29,30,31,32] and second, a broadly compatible bank vole PrP (BVPrP) sequence.”
BackgroundMolecular pathology of human prion disease
Wadsworth, J. D. F., & Collinge, J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0735-5 · Cited by 119
“According to the widely accepted ‘protein-only’ hypothesis [47], host-encoded cellular prion protein (PrP) is converted to an alternative form designated PrP [22, 27, 30, 100, 129].”
BackgroundEndocytosis of Prion Protein Is Required for ERK1/2 Signaling Induced by Stress-Inducible Protein 1
Caetano, F. A., Lopes, M. H., Hajj, G. N. M., Machado, C. F., Pinto Arantes, C., Magalhaes, A. C., Vieira, M. D. P. B., Americo, T. A., Massensini, A. R., Priola, S. A., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1701-08.2008 · Cited by 106
“PrP Sc interacts with PrP C at the cell surface or along the endocytic pathway (Caughey and Raymond, 1991; Caughey and Baron, 2006), but how this interaction imprints novel information to cause disease in the host is a matter of debate.”
BackgroundGenesis of Mammalian Prions: From Non-infectious Amyloid Fibrils to a Transmissible Prion Disease
Makarava, N., Kovács, G. G., Savtchenko, R. S., Alexeeva, I., Budka, H., Rohwer, R. G., & Baskakov, I. V. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002419 · Cited by 113
Schneider, S. A., Walker, R. H., & Bhatia, K. P. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0606 · Cited by 103
Intriguing nucleic-acid-binding features of mammalian prion protein
Silva, J. L., Lima, L. M. T. R., Foguel, D., & Cordeiro, Y. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.11.003 · Cited by 112
Singh, A., Kong, Q., Luo, X., Petersen, R. B., Meyerson, H., & Singh, N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006115 · Cited by 99
“pathogenesis of prion disorders and justifying the focus [2].”
BackgroundVeith, N., Plattner, H., Stuermer, C. A. O., Schulz‐Schaeffer, W., & Bürkle, A. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.08.001 · Cited by 97
“proteinase K (PK) (Taraboulos et al., 1990; Caughey and Baron, 2006).”
The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target
Wolfe, M. S. (2012) · Scientifica · doi:10.6064/2012/796024 · Cited by 96
“Although the exact identity of the fragment is unknown, expression of an approximate recombinant version, tau [45-230], can lead to apoptosis in cell culture [118].”
BackgroundDegenerating Synaptic Boutons in Prion Disease
Šišková, Z., Page, A. M., O'Connor, V. M., & Perry, V. H. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090372 · Cited by 109
“Recent evidence suggests, however, that it is not the amyloid per se that is the neurotoxic element but it is oligomers of the Aß peptide(4) or misfolded PrP that may be critical in causing neuronal dysfunction and precipitating neurodegeneration.(5) Whatever the nature of the toxic agent there is a growing body of da…”
BackgroundGlypican-1 Mediates Both Prion Protein Lipid Raft Association and Disease Isoform Formation
Taylor, D. R., Whitehouse, I. J., & Hooper, N. M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000666 · Cited by 100
“Like heparan sulfate, many of the anti-prion compounds identified to date are, or have the capacity to stack into, large polyanionic chains [45].”
BackgroundAbnormal Brain Iron Homeostasis in Human and Animal Prion Disorders
Singh, A., Isaac, A. O., Luo, X., Mohan, M. L., Cohen, M. L., Chen, F., Kong, Q., Bartz, J., & Singh, N. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000336 · Cited by 92
“It is notable that Tf levels are unlikely to be affected by secondary factors such as astrogliosis and neuronal loss, prominent features of end-stage prion disease [11,12], and reflect neuronal iron status.”
BackgroundEvidence for Stepwise Formation of Amyloid Fibrils by the Mouse Prion Protein
Jain, S., & Udgaonkar, J. B. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.052 · Cited by 95
Prion Protein and Its Conformational Conversion: A Structural Perspective
Surewicz, W. K., & Apostol, M. I. (2011) · Topics in current chemistry · doi:10.1007/128_2011_165 · Cited by 101
Santos, T. G., Silva, I. R., Costa‐Silva, B., Lepique, A. P., Martins, V. R., & Lopes, M. H. (2011) · Stem Cells · doi:10.1002/stem.664 · Cited by 93
Microglia and Synapse: Interactions in Health and Neurodegeneration
Šišková, Z., & Tremblay, M.-È. (2013) · Neural Plasticity · doi:10.1155/2013/425845 · Cited by 80
“The misfolded, protease-resistant protein was long implicated in the demise of neurons; however, recent evidence suggests that it might be the protein oligomers, as in AD, that precipitate the synaptic dysfunction [78].”
Bravo, R., Arimon, M., Valle‐Delgado, J. J., García, R., Durany, N., Castel, S., Cruz, M., Ventura, S., & Fernàndez‐Busquets, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709870200 · Cited by 84
Han, Y., Lee, J. H., Yoon, Y. M., Yun, C. W., Noh, H., & Lee, S. H. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.310 · Cited by 77
“protease-sensitive, and tethered to the cell membrane by a glycosyl phosphatidyl inositol anchor.(11) Meanwhile, the abnormal form of PrP is commonly multimeric, aggregated, and protease-resistant, and is associated with neurotoxicity”
BackgroundPrions and protein-folding diseases: Review: Prions and protein-folding diseases
Norrby, E. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02387.x · Cited by 75
Caetano, F. A., Beraldo, F. H., Hajj, G. N. M., Guimaraes, A. L., Jürgensen, S., Wasilewska-Sampaio, A. P., Hirata, P. H. F., Souza, I., Machado, C. F., Wong, D. Y.-L., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07225.x · Cited by 74
Prion protein and its ligand stress inducible protein 1 regulate astrocyte development
Arantes, C., Nomizo, R., Lopes, M. H., Hajj, G. N. M., Lima, F. R. S., & Martins, V. R. (2009) · Glia · doi:10.1002/glia.20861 · Cited by 75
Pathologic Prion Protein Infects Cells by Lipid-Raft Dependent Macropinocytosis
Wadia, J. S., Schaller, M., Williamson, R. A., & Dowdy, S. F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003314 · Cited by 73
“, suggesting that the second lysine-rich transduction motif may be sufficient in the absence of the N-terminal domain to direct cellular entry. Small amounts of cytoplasmic PrP have been reported to cause neurotoxicity”
BackgroundUre2p Function Is Enhanced by Its Prion Domain in Saccharomyces cerevisiae
Shewmaker, F. P., Mull, L., Nakayashiki, T., Masison, D. C., & Wickner, R. B. (2007) · Genetics · doi:10.1534/genetics.107.074153 · Cited by 71
“One particular class of amyloid diseases is the collection of diseases known as the transmissible spongiform encephalopathies (TSEs), which are apparently caused by an infectious amyloid of PrP and are always fatal (Caughey and Baron 2006).”
BackgroundPrion and Non-prion Amyloids of the HET-s Prion forming Domain
Sabaté, R., Baxa, U., Benkemoun, L., de Groot, N. S., Salin, B., Maddelein, M., Malato, L., Ventura, S., Steven, A. C., & Saupe, S. J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.014 · Cited by 83
Hamley, I. W. (2007) · Angewandte Chemie · doi:10.1002/ange.200700861 · Cited by 71
Prion Protein Misfolding, Strains, and Neurotoxicity: An Update from Studies on Mammalian Prions
Poggiolini, I., Saverioni, D., & Parchi, P. (2013) · International Journal of Cell Biology · doi:10.1155/2013/910314 · Cited by 77
“Alternatively, PrPC may disrupt the endosomal compartment after being internalized [237].”
BackgroundSequestration of essential proteins causes prion associated toxicity in yeast
Vishveshwara, N., Bradley, M. E., & Liebman, S. W. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06836.x · Cited by 72
Cells Expressing Anchorless Prion Protein Are Resistant to Scrapie Infection
McNally, K. L., Ward, A. E., & Priola, S. A. (2009) · Journal of Virology · doi:10.1128/jvi.02412-08 · Cited by 68
“PrP-res usually correlates with infectivity, although whether other factors are necessary for TSE infection has not been conclusively established (6, 9, 11).”
BackgroundHeat shock factor 1 regulates lifespan as distinct from disease onset in prion disease
Steele, A. D., Hütter, G., Jackson, W. S., Heppner, F. L., Borkowski, A. W., King, O. D., Raymond, G. J., Aguzzi, A., & Lindquist, S. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806319105 · Cited by 68
“tures, (2) systemic inflammation, (3) neonatal lethality, and (4) cardiac ischemia.”
BackgroundWadsworth, J. D. F., Asante, E. A., & Collinge, J. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01129.x · Cited by 67
Cobb, N. J., Apetri, A. C., & Surewicz, W. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806701200 · Cited by 72
Prion Variants and Species Barriers Among Saccharomyces Ure2 Proteins
Edskes, H. K., McCann, L. M., Hebert, A. M., & Wickner, R. B. (2009) · Genetics · doi:10.1534/genetics.108.099929 · Cited by 74
“The PrP protein, product of the Sinc gene, is believed to be the protein whose amyloid form is infectious (Dickinson et al. 1968; Bolton et al. 1982; Caughey and Baron 2006; Aguzzi et al. 2008).”
BackgroundSingh, A., Mohan, M. L., Isaac, A. O., Luo, X., Petrák, J., Vyoral, D., & Singh, N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004468 · Cited by 67
“ogy in mice over-expressing normal or mutant PrP in the wrong cellular compartment in the absence of detectable PrP, suggesting the presence of additional pathways of neurotoxicity [1,7].”
BackgroundRedox Control of Prion and Disease Pathogenesis
Singh, N., Singh, A., Das, D., & Mohan, M. L. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2628 · Cited by 62
“The prion disorders of humans and animals and the underlying cause of disease are described in Table 2 (2, 40, 53, 176).”
InfluentialCellular Prion Protein Promotes Regeneration of Adult Muscle Tissue
Stella, R., Massimino, M. L., Sandri, M., Sorgato, M. C., & Bertoli, A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01040-09 · Cited by 69
Laferrière, F., Tixador, P., Moudjou, M., Chapuis, J., Sibille, P., Herzog, L., Reine, F., Jaumain, E., Laude, H., Rézaei, H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003702 · Cited by 66
“(for review [48]) could also affect PrP density [33].”
BackgroundHeparin binding confers prion stability and impairs its aggregation
Vieira, T. C. R. G., Cordeiro, Y., Caughey, B. W., & Silva, J. L. (2014) · The FASEB Journal · doi:10.1096/fj.13-246777 · Cited by 63
“Some researchers have suggested that these molecules directly convert the protein into its protease-resistant form (22, 29), whereas others have proposed that these molecules block the interaction of PrP with endogenous GAGs and/or decrease the PrP content at the cell surface (18, 30), resulting in protective action (…”
BackgroundSelf-citationRole of the Highly Conserved Middle Region of Prion Protein (PrP) in PrP−Lipid Interaction
Wang, F., Yin, S., Wang, X., Zha, L., Sy, M., & Ma, J. (2010) · Biochemistry · doi:10.1021/bi101146v · Cited by 65
“The transmissionof priondisease ismediated by an unusual infectious agent, which is composed of a pathogenic conformer of the normal prion protein (PrP) (1, 4-6).”
BackgroundMeasuring prions by bioluminescence imaging
Tamgüney, G., Francis, K. P., Giles, K., Lemus, A., DeArmond, S. J., & Prusiner, S. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907339106 · Cited by 61
“�1 12 1 11 11 1 11 11 �2 12 0 12 12 0 12 12 �3 12 0 12 12 0 12 12 �4 12 6 6 6 3 9 9 �5 12 2 8 8 3 9 9 �6 12 1 11 8 1 11 8 �7 12 2 10 3 2 10 5 (1) �8 12 5 7 2 2 10 7 (2) �9 12 2 10 0 2 10 3 (3) �10 12 0 12 0 0 12 1 (1)”
Vieira, T. C. R. G., Reynaldo, D. P., Gomes, M. P. B., Almeida, M. S., Cordeiro, Y., & Silva, J. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106725p · Cited by 59
Prion Proteins with Pathogenic and Protective Mutations Show Similar Structure and Dynamics
Bae, S.-H., Legname, G., Serban, A. V., Prusiner, S. B., Wright, P. E., & Dyson, H. J. (2009) · Biochemistry · doi:10.1021/bi900923b · Cited by 60
“Prion diseases are a group of rare but fatal neurodegenerative disorders that pathologically manifest accumulation of proteaseresistant aggregates of prion protein (PrP)(1) in affected brain regions (1-4).”
BackgroundStructure of the Flexible Amino-Terminal Domain of Prion Protein Bound to a Sulfated Glycan
Taubner, L. M., Bienkiewicz, E. A., Copié, V., & Caughey, B. W. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.075 · Cited by 64
Self-citationLee, J. H., Han, Y., & Lee, S. H. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12385 · Cited by 57
“The normal cellular prion protein (PrP) is a highly conserved and ubiquitous glycoprotein, which is mostly tethered to the cell surface by the glycosylphosphatidylinositol anchor.(25) Although the abnormal form of the prion protein (PrP) is involved in the pathogenesis of prion diseases and neurodegenerative disorders…”
BackgroundArena, G., Mendola, D. L., Pappalardo, G., Sóvágó, I., & Rizzarelli, E. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.038 · Cited by 58
Taguchi, Y., Shi, Z., Ruddy, B. M., Dorward, D. W., Greene, L. E., & Baron, G. S. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-06-0635 · Cited by 55
“PrPsen binds a variety of cellular components in interactions that are likely involved in executing its diverse physiological functions (Caughey and Baron, 2006).”
BackgroundSelf-citationJen, A., Parkyn, C. J., Mootoosamy, R. C., Ford, M. J., Warley, A., Liu, Q., Bu, G., Baskakov, I. V., Moestrup, S., McGuinness, L., et al. (2010) · Journal of Cell Science · doi:10.1242/jcs.058099 · Cited by 53
“Recent reviews (e.g. Caughey and Baron, 2006; Krammer et al., 2009; Linden et al., 2008) provide a wider perspective on interactions proposed for PrP with other receptors, and their implication for prion infection.”
BackgroundMcAdam, A. J., & Sharpe, A. H. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50013-4 · Cited by 58
Prions: Beyond a Single Protein
Das, A. S., & Zou, W. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-15 · Cited by 68
“Given the experimental failure to recapitulate this conversion with protein-only substrates, a large body of evidence suggests that other macromolecules may be involved (88, 89).”
BackgroundWong, B. X., & Duce, J. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00081 · Cited by 49
“Despite a reduced affinity compared to other transitional metals, iron binds A β and induces A β aggregation (Huang et al., 2004; Ha et al., 2007; Bousejra-ElGarah et al., 2011).”
BackgroundAllosteric function and dysfunction of the prion protein
Linden, R., Cordeiro, Y., & Lima, L. M. T. R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0847-7 · Cited by 56
Discovery of a Class of Diketopiperazines as Antiprion Compounds
Bolognesi, M. L., Tran, H. N. A., Staderini, M., Monaco, A., López‐Cobeñas, A., Bongarzone, S., Biarnés, X., López‐Alvarado, P., Cabezas, N., Caramelli, M., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.201000133 · Cited by 49
A Mutant Prion Protein Sensitizes Neurons to Glutamate-Induced Excitotoxicity
Biasini, E., Unterberger, U., Solomon, I. H., Massignan, T., Senatore, A., Bian, H.-J., Voigtländer, T., Bowman, F. P., Bonetto, V., Chiesa, R., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3406-12.2013 · Cited by 50
“…prion propagation involves conformational conversion of the cellular prion protein (PrP C) into the scrapie prion protein (PrP Sc) is now widely accepted, the mechanism by which prions cause neurodegeneration is still uncertain (Caughey and Baron, 2006; Harris and True, 2006; Aguzzi et al., 2007).”
BackgroundPrion Protein and Metal Interaction: Physiological and Pathological Implications
Singh, N., Das, D., Singh, A., & Mohan, M. L. (2010) · The Prion Protein · doi:10.21775/9781912530076.04 · Cited by 48
“Deposits of PrPSc in the brain parenchyma are considered the principal cause of neurotoxicity, though the pathways involved in this process are poorly understood (Prusiner, 1998; Aguzzi and Polymenidou, 2004, Caughey and Baron, 2006).”
Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation
Valiente‐Gabioud, A. A., Miotto, M., Chesta, M. E., Lombardo, V. A., Binolfi, A., & Fernández, C. O. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00507 · Cited by 51
Can misfolded proteins be beneficial? The HAMLET case
Pettersson-Kastberg, J., Aits, S., Gustafsson, L., Mossberg, A., Storm, P., Trulsson, M., Persson, F., Mok, K. H., & Svanborg, C. (2009) · Annals of Medicine · doi:10.1080/07853890802502614 · Cited by 48
Prion Pathogenesis is Independent of Caspase-12
Steele, A. D., Hetz, C., Yi, C., Jackson, W., Borkowski, A., Yuan, J., Wollmann, R. L., & Lindquist, S. (2007) · Prion · doi:10.4161/pri.1.4.5551 · Cited by 45
Molecular motions in drug design: the coming age of the metadynamics method
Biarnés, X., Bongarzone, S., Vargiu, A. V., Carloni, P., & Ruggerone, P. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9415-3 · Cited by 44
Nanopore detection of antibody prion interactions
Madampage, C. A., Andrievskaia, O., & Lee, J. S. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.08.028 · Cited by 45
Prions and peripheral nerves: A deadly rendezvous
Heikenwälder, M. F., Julius, C., & Aguzzi, A. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21246 · Cited by 50
Evaluation of drugs for treatment of prion infections of the central nervous system
Riemer, C., Burwinkel, M., Schwarz, A., Gültner, S., Mok, S. W. F., Heise, I., Holtkamp, N., & Baier, M. (2008) · Journal of General Virology · doi:10.1099/vir.0.83281-0 · Cited by 48
“However, underlying pathomechanisms in prion infections of the CNS are still elusive (Burwinkel et al., 2004; Caughey & Baron, 2006).”
BackgroundA Structural Overview of the Vertebrate Prion Proteins
Pastore, A., & Zagari, A. (2007) · Prion · doi:10.4161/pri.1.3.5281 · Cited by 51
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 45
Metadata
- Authors
- Caughey, B., & Baron, G. S.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Caughey, Byron
- Baron, Gerald S.
- Venue
- Nature
- Published
- 2006-10
- Volume
- 443
- Issue
- 7113
- Pages
- 803-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2057579163
- Cited by
- 295
- References
- 96
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 11 · 2013: 14 · 2012: 19
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- prions, prion disease, prion protein, prion pathogenesis
- MeSH terms
- Animals, Copper, Humans, Ligands, Prions, Prion Diseases, Glycosylphosphatidylinositols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.